Merck (NYSE:MRK) reported a Q2 non-GAAP loss of $2.06 per share, down from EPS of $1.87 a year ago.
Analysts polled by Capital IQ expected a loss of $2.18.
Sales for the quarter ended June 30 were $15.04 billion, up from $14.59 billion a year earlier.
Analysts surveyed by Capital IQ expected $14.44 billion.
The company said it now expects 2023 non-GAAP EPS of $2.95 to $3.05, compared with the prior estimate of $6.88 to $7. Analysts surveyed by Capital IQ expect $2.92.
The company now expects 2023 sales to be between $58.6 billion to $59.6 billion, compared with the previous projection of $57.7 billion to $58.9 billion. Analysts polled by Capital IQ expect $58.65 billion.